Press Releases

05-24-2023	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
05-10-2023	Pliant Therapeutics to Participate in Upcoming Investor Events
05-09-2023	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
04-30-2023	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
04-12-2023	Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
03-27-2023	Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
03-13-2023	Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
03-09-2023	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
03-08-2023	Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
03-01-2023	Pliant Therapeutics to Participate in Upcoming Investor Events